famciclovir Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals bicyclic heterocycle compounds 1128 104227-87-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • famciclovir
  • famcivir
  • famcyclovir
  • famtrex
  • famvir
An aminopurine derivative and prodrug of penciclovir which is a competitive inhibitor of herpes simplex 2 DNA polymerase. It is used to treat HERPES SIMPLEX VIRUS INFECTION.
  • Molecular weight: 321.34
  • Formula: C14H19N5O4
  • CLOGP: 0.08
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 1
  • TPSA: 122.22
  • ALOGS: -2.39
  • ROTB: 9

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.75 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 250 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 77.80 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 77 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
June 29, 1994 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Herpes zoster 31.25 18.00 32 3571 67840 46614619
CD4 lymphocytes decreased 25.45 18.00 8 3595 1602 46680857
Plasma cell myeloma 22.35 18.00 22 3581 44456 46638003
Necrotising retinitis 22.02 18.00 5 3598 288 46682171
Cytarabine syndrome 22.00 18.00 4 3599 74 46682385
Aplastic anaemia 19.53 18.00 10 3593 7143 46675316
Acute myeloid leukaemia 19.02 18.00 13 3590 15765 46666694

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Meralgia paraesthetica 31.15 20.99 6 1988 179 29950305
Tuberculosis liver 30.12 20.99 5 1989 62 29950422
Herpes zoster 28.19 20.99 20 1974 29923 29920561
Cutaneous vasculitis 21.76 20.99 8 1986 2983 29947501
Graft versus host disease in liver 21.07 20.99 6 1988 996 29949488

Pharmacologic Action:

SourceCodeDescription
ATC J05AB09 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
ATC S01AD07 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Antivirals
FDA MoA N0000020060 DNULL Polymerase Inhibitors
FDA EXT N0000175459 Nucleoside Analog
CHEBI has role CHEBI:36044 anti-virus drug
CHEBI has role CHEBI:50266 prodrugs
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
FDA EPC N0000180187 Herpes Simplex Virus Nucleoside Analog DNULL Polymerase Inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Herpes zoster indication 4740000 DOID:8536
Recurrent herpes simplex labialis indication 402892009
Recurrent genital herpes simplex indication 402894005
Suppression of Recurrent Herpes Simplex Infection indication
Recurrent Mucocutaneous Herpes Simplex in Human Immunodeficiency Virus Infected Patients indication
Suppression of Recurrent Herpes Simplex Infection in HIV off-label use
Prevention of Herpes Zoster in Immunocompromised Patient off-label use
Kidney disease contraindication 90708001 DOID:557

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.86 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA polymerase catalytic subunit Enzyme INHIBITOR WOMBAT-PK CHEMBL
DNA polymerase catalytic subunit Enzyme WOMBAT-PK

External reference:

IDSource
4020882 VUID
N0000148380 NUI
D00317 KEGG_DRUG
4020882 VANDF
C0209227 UMLSCUI
CHEBI:4974 CHEBI
CHEMBL880 ChEMBL_ID
DB00426 DRUGBANK_ID
D000077595 MESH_DESCRIPTOR_UI
3324 PUBCHEM_CID
6438 INN_ID
QIC03ANI02 UNII
151733 RXNORM
119086 MMSL
1730 MMSL
4712 MMSL
d03775 MMSL
004470 NDDF
387557001 SNOMEDCT_US
96097002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Famciclovir HUMAN PRESCRIPTION DRUG LABEL 1 0093-8117 TABLET, FILM COATED 125 mg ORAL ANDA 25 sections
Famciclovir HUMAN PRESCRIPTION DRUG LABEL 1 0093-8118 TABLET, FILM COATED 250 mg ORAL ANDA 25 sections
Famciclovir HUMAN PRESCRIPTION DRUG LABEL 1 0093-8119 TABLET, FILM COATED 500 mg ORAL ANDA 25 sections
Famciclovir HUMAN PRESCRIPTION DRUG LABEL 1 16714-614 TABLET 125 mg ORAL ANDA 23 sections
Famciclovir HUMAN PRESCRIPTION DRUG LABEL 1 16714-615 TABLET 250 mg ORAL ANDA 23 sections
Famciclovir HUMAN PRESCRIPTION DRUG LABEL 1 16714-616 TABLET 500 mg ORAL ANDA 23 sections
Famciclovir HUMAN PRESCRIPTION DRUG LABEL 1 17856-0705 TABLET, FILM COATED 250 mg ORAL ANDA 25 sections
Famciclovir HUMAN PRESCRIPTION DRUG LABEL 1 17856-0706 TABLET, FILM COATED 125 mg ORAL ANDA 25 sections
Famciclovir HUMAN PRESCRIPTION DRUG LABEL 1 17856-0708 TABLET, FILM COATED 500 mg ORAL ANDA 25 sections
Famciclovir Human Prescription Drug Label 1 33342-024 TABLET, FILM COATED 125 mg ORAL ANDA 26 sections
Famciclovir Human Prescription Drug Label 1 33342-025 TABLET, FILM COATED 250 mg ORAL ANDA 26 sections
Famciclovir Human Prescription Drug Label 1 33342-026 TABLET, FILM COATED 500 mg ORAL ANDA 26 sections
Famciclovir HUMAN PRESCRIPTION DRUG LABEL 1 42291-414 TABLET, FILM COATED 125 mg ORAL ANDA 25 sections
Famciclovir HUMAN PRESCRIPTION DRUG LABEL 1 42291-415 TABLET, FILM COATED 250 mg ORAL ANDA 25 sections
Famciclovir HUMAN PRESCRIPTION DRUG LABEL 1 42291-416 TABLET, FILM COATED 500 mg ORAL ANDA 25 sections
Famciclovir HUMAN PRESCRIPTION DRUG LABEL 1 54868-5905 TABLET, FILM COATED 500 mg ORAL ANDA 28 sections
Famciclovir HUMAN PRESCRIPTION DRUG LABEL 1 55289-168 TABLET, FILM COATED 500 mg ORAL ANDA 25 sections
FAMCICLOVIR HUMAN PRESCRIPTION DRUG LABEL 1 60429-359 TABLET, FILM COATED 125 mg ORAL ANDA 23 sections
FAMCICLOVIR HUMAN PRESCRIPTION DRUG LABEL 1 60429-360 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
FAMCICLOVIR HUMAN PRESCRIPTION DRUG LABEL 1 60429-361 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections
FAMCICLOVIR HUMAN PRESCRIPTION DRUG LABEL 1 60505-3245 TABLET, FILM COATED 125 mg ORAL ANDA 23 sections
FAMCICLOVIR HUMAN PRESCRIPTION DRUG LABEL 1 60505-3246 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
FAMCICLOVIR HUMAN PRESCRIPTION DRUG LABEL 1 60505-3247 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections
FAMCICLOVIR HUMAN PRESCRIPTION DRUG LABEL 1 63187-919 TABLET 250 mg ORAL ANDA 24 sections
FAMCICLOVIR HUMAN PRESCRIPTION DRUG LABEL 1 63187-920 TABLET 500 mg ORAL ANDA 24 sections
Famciclovir HUMAN PRESCRIPTION DRUG LABEL 1 63187-998 TABLET, FILM COATED 500 mg ORAL ANDA 24 sections
Famciclovir Human Prescription Drug Label 1 63629-7890 TABLET, FILM COATED 500 mg ORAL ANDA 24 sections
Famciclovir Human Prescription Drug Label 1 64980-349 TABLET, FILM COATED 125 mg ORAL ANDA 26 sections
Famciclovir Human Prescription Drug Label 1 64980-350 TABLET, FILM COATED 250 mg ORAL ANDA 26 sections
Famciclovir Human Prescription Drug Label 1 64980-351 TABLET, FILM COATED 500 mg ORAL ANDA 26 sections